Qualitek Labs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 20/12/2025 ,inter alia, to consider and approve issuance of NCDs, creation of ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Qualitek Labs has called a board meeting on 20 December 2025 to consider issuing secured, unlisted, redeemable Non-Convertible Debentures (NCDs) on a private placement basis. The board will also approve creating a charge on company assets and providing corporate and personal guarantees to back the NCD issue. A Debenture Trustee will be appointed, and an Extraordinary General Meeting (EGM) of shareholders will be convened to seek approval under Section 180(1)(a) of the Companies Act, which is required for pledging company assets. The specific amount, tenure, and interest rate of the NCDs have not been disclosed in this intimation.
This is a debt-raising move, not equity, so there is no immediate dilution risk for shareholders. However, pledging company assets and giving personal guarantees signals the company is taking on secured borrowing, which adds financial obligation and risk if cash flows weaken. Investors should watch the EGM notice and the NCD terms (size, coupon, end-use) for clarity on how the funds will be deployed.